The pink-eyed dilution (p) gene plays a central role in the control of human pigmentation. Mutations in the p gene cause oculocutaneous albinism type 2 and other forms hypopigmentation, and polymorphisms in the p gene have been associated with normal variations in skin and eye color. We propose to concentrate our efforts on the study of the biology and function of the pink-eyed dilution gene product and the control of tyrosinase processing. During the next period of support, three major specific aims will be pursued. We will: *Explore by cellular, molecular and genetic approaches the role of the p gene product in tyrosinase processing and trafficking in melanocytic and nonmelanocytic cells. *Evaluate the subcellular effects of and targets for pharmacologic agents that can correct for the lack of p expression in melanocytic and nonmelanocytic cells. *Examine the role of glutathione in tyrosinase processing and the role of the p gene product in melanocyte glutathione metabolism and redox using both mammalian and yeast-based systems, and a combination of cellular, molecular, pharmacologic and genetic techniques. We believe that the proposed experimentation will greatly advance our understanding of the pathogenesis of OCA2, of normal variations in ethnic skin coloration, and of pigmentary defects in amelanotic melanomas, in addition to furthering our knowledge regarding the normal cellular and molecular process of pigmentation. Moreover, our results are likely to result directly in potential pharmacologic therapies of OCA2.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR041880-12
Application #
7103400
Study Section
Special Emphasis Panel (ZRG1-ACTS (01))
Program Officer
Baker, Carl
Project Start
1994-03-15
Project End
2009-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
12
Fiscal Year
2006
Total Cost
$375,440
Indirect Cost
Name
New York University
Department
Dermatology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
De Filippo, Elisabetta; Schiedel, Anke C; Manga, Prashiela (2017) Interaction between G Protein-Coupled Receptor 143 and Tyrosinase: Implications for Understanding Ocular Albinism Type 1. J Invest Dermatol 137:457-465
De Filippo, Elisabetta; Manga, Prashiela; Schiedel, Anke C (2017) Identification of Novel G Protein-Coupled Receptor 143 Ligands as Pharmacologic Tools for Investigating X-Linked Ocular Albinism. Invest Ophthalmol Vis Sci 58:3118-3126
Arowojolu, Omotayo A; Orlow, Seth J; Elbuluk, Nada et al. (2017) The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone. Exp Dermatol 26:637-644
Manga, Prashiela; Elbuluk, Nada; Orlow, Seth J (2016) Recent advances in understanding vitiligo. F1000Res 5:
Murase, Daiki; Hachiya, Akira; Fullenkamp, Rachel et al. (2016) Variation in Hsp70-1A Expression Contributes to Skin Color Diversity. J Invest Dermatol 136:1681-1691
Doudican, Nicole A; Wen, Shih Ya; Mazumder, Amitabha et al. (2014) Identification of agents that promote endoplasmic reticulum stress using an assay that monitors luciferase secretion. J Biomol Screen 19:575-84
Wang, Claire Q F; Akalu, Yemsratch T; Suarez-Farinas, Mayte et al. (2013) IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol 133:2741-2752
Cheng, Tsing; Orlow, Seth J; Manga, Prashiela (2013) Loss of Oca2 disrupts the unfolded protein response and increases resistance to endoplasmic reticulum stress in melanocytes. Pigment Cell Melanoma Res 26:826-34
Toosi, Siavash; Orlow, Seth J; Manga, Prashiela (2012) Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol 132:2601-9
Manga, Prashiela; Orlow, Seth J (2011) Informed reasoning: repositioning of nitisinone to treat oculocutaneous albinism. J Clin Invest 121:3828-31

Showing the most recent 10 out of 13 publications